Intelligent Investors Den!
We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
Sign up Now and Gain Access to Exciting Opportunities from Investor and Resource Space!
By submitting your details and clicking on the SIGN UP button you agree to Kalkine’s Free Trial-Terms of Use and consent to receive marketing offers including to be contacted by email or phone, as set out in our Privacy Policy Any calls will be made by Kalkine Pty Ltd or Kalkine Solutions Private Limited on our behalf. You also agree that Kalkine/KSPL can give you its Financial Services Guide by electronic means (including by website link or email). Before accessing our services, please read the Financial Services Guide available here.
By creating account you will get access to hot stocks & personalised emails
Any calls will be made by Kalkine Pty Ltd or Kalkine Solutions Private Limited on our behalf.
Last update at 2024-10-17T05:10:00Z
Aroa Biosurgery Limited (ASX:ARX) Is Expected To Breakeven In The Near Future
AROA BIOSURGERY ANNOUNCES HALF YEAR RESULTS
DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY
Shareholders in Aroa Biosurgery (ASX:ARX) are in the red if they invested a year ago
Breakeven On The Horizon For Aroa Biosurgery Limited (ASX:ARX)
An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 31% Undervalued
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
Investors one-year losses grow to 43% as the stock sheds NZ$56m this past week
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Real-World Data Shows Aroa Biosurgery’s Endoform™ Natural Achieves Significantly Improved Wound Closure for Diabetic Foot Ulcers Compared to Traditional Collagen Dressings
Sector: Healthcare Industry: Medical Devices
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
64 Richard Pearse Drive, Auckland, New Zealand, 2022
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.